Progenity Inc
PROG
Get informed when a big investor buys or sells
+ FollowMarket Cap$162.04M
Close$
Share Statistics
| Market cap | $162.04 Million |
|---|---|
| Enterprise Value | $197.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.49 |
| Beta | 0 |
| Outstanding Shares | 183,201,663 |
Return
| Return on Equity | 29.58% |
|---|---|
| Return on Assets | -217.44% |
| Return on Invested Capital | 57.47% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.88 |
| Enterprise Value to Revenue | 111.93 |
| Enterprise Value to EBIT | -3.24 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | -0.36 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Progenity Inc
58 employees
CEO: Harry Stylli Biora Therapeutics, Inc. operates as a biotechnology company, primarily focused on developing innovative oral biotherapeutics. The company's core efforts include: 1. Targeted Therapeutics Program: This initiative employs an advanced, ing...